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BPH AND IPSS SCORES EVALUATED AFTER 6 MONTHS
ACCORDING TO THE TYPE OF DISEASE MANAGEMENT
Marionneau N, Myon E, Charles T
Pierre Fabre, Boulogne-Billancourt, France
OBJECTIVES: Benign prostatic hyperplasia (BPH) occurs fre-
quently in middle-aged and elderly men. Recent epidemiologic
data suggest that 50% of men aged of 50 years are concerned.
Because of the growing elderly population in the industrialised
countries, the management of the disease is becoming a major
public health problem. A wide variety of medical treatment is
available, and the ﬁnancial burden associated to it is increasing.
This is a public health problem with a number of diagnostic,
therapeutic and economic facets. The severity of the problem is
assessed by the score obtained on the IPSS, a well known and
recognised questionnaire. METHODS: More than 700 patients
with BPH diagnosed for less than 3 months will be included in
the CHOQ program by 250 general practitioners. Every 6-
months, and for at least 3-years, the patient and his partner will
ﬁll out a quality of life questionnaire. This questionnaire is com-
posed of a generic instrument that assesses the general health
condition, and 5 speciﬁc instruments that investigate the conse-
quences of the BPH on sexuality, sleeping and urinary symptoms.
RESULTS: Using a follow-up cohort study, we isolated two
groups presenting a recently diagnosed BPH: the ﬁrst patient
population was kept under watchful waiting (n = 101) versus a
second patient population undergoing treatment with Serenoa
repens (n = 112). For the patients under watchful waiting, the
IPSS score was respectively 11.8 (5.7) and 10.9 (6.7) upon
patient inclusion and after 6 months. This difference is not sta-
tistically signiﬁcant. However, for the patients treated with
Serenoa repens, the IPSS score was respectively 14.3 (6.6) and
11.9 (5.7) upon patient inclusion and after 6 months. The noted
difference is statistically signiﬁcant (p < 0.0001). CONCLU-
SIONS: Patients suffering from a recently diagnosed BPH and
treated with Serenoa repens thus showed a statistically signiﬁ-
cant improvement as demonstrated by the IPSS score.
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OBJECTIVES: To compare the results obtained with the IPSS
administered by GP (GP-IPSS) versus a self administered ques-
tionnaire (patient-IPSS). METHODS: A total of 338 recently
diagnosed BPH patients were involved in the analyses. For each
of them, their GP (General Practionner) ﬁlled an GP-IPSS ques-
tionnaire in according to their knowledge of their patients. The
patient completed the patient-IPSS questionnaire himself and
send it back to data management center through a prepaid enve-
lope to avoid patient’s answers to be viewed by the GP. Bland &
Altman method was chosen to visualize individual difference and
to quantify the bias. RESULTS: On average GP overestimated
by 1.3 points [0.9–1.7] 95% the IPSS compared to patient self
evaluation. Individual discrepancies reached 3 points or more
among 42% of patients. The results of GP-IPSS were signiﬁcantly
higher at 6 months, 12 months and 18 months taking into
account Bonferoni correction. CONCLUSIONS: There was a
statistically signiﬁcant bias between GP’s administered IPSS and
self administered IPSS. We recommend to always keeping the
same IPSS administration’s mode during the course of a clinical
trial.
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ESTIMATION AND ANALYSIS OF DIRECT MEDICAL COST OF
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Secondary hyperparathyroidism (SHPT) is frequently observed
in dialysis patients leading to costly to treat health complications.
OBJECTIVES: To assess whether direct medical costs signiﬁ-
cantly vary with SHPT conditions. METHODS: Direct medical
cost and resource use data were retrospectively collected from
patient medical ﬁles and invoices of 75 dialysis patients over
maximum period of 2 years prior to death in 3 dialysis centres
in Belgium. Total collection period was segmented into two
SHPT condition episodes deﬁned by PTH values £ or >300pg/
mL, using linear interpolation lines between subsequent PTH
measurements. Costs were retrieved from hospital invoices,
including start and stop date of each bill and cost category (hos-
pitalisations, medications, dialysis, laboratory tests, honoraria,
and other). To overcome problems of incomplete invoices, an
invoice coverage factor was developed comparing available
invoices with health care resource utilisation from medical ﬁles.
Periods with insufﬁcient coverage were discarded. Resource use
and costs were attributed to each individual PTH condition
episode. Statistical modeling: Because of heavily skewed cost
data, incomplete data sets, the need to adjust cost results for time
to death and centre effect, mixed models on non-transformed
and log-transformed costs and General Linear Model (GLM)
with a gamma response probability distribution and a loglink
function were used. RESULTS: Results expressed as mean cost
per day show that periods with elevated PTH-values lead to
higher costs compared to normal periods (average cost-difference
per day: approximately €50; p < 0.05). Results will further be
discussed regarding distribution of residuals, and hypothesis
testing. To assess robustness of results, three sensitivity analyses
were performed: analysis on subjects having experienced both
PTH conditions before death; analysis over different observation
periods using 6 months incremental time periods; cost deprecia-
tion factor. CONCLUSIONS: The statistical method allowed
obtaining robust and valuable cost estimates for different SHPT
conditions.
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